Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.

1: Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; "Given the recent approval by the US Food and Drug Administration of an anti-programmed cell death protein 1 agent as a first-line therapy for patients with advanced non-small cell lung cancer, programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC) testing has become routine in pathology laboratories in the United States. Each pathology laboratory needs to select a PD-L1 IHC assay among the multiple assays available, conduct appropriate optimization and validation processes, and pay close attention to appropriate preanalytical tissue handling and the selection of optimal tissue samples."

TimAllenMDJD